The Oncology Unit of the HPA Health Group has a new diagnostic method, known as Liquid Biopsy and Circulating Tumor DNA (ctDNA), the group announced today.
In a note, the HPA explains that it is a "minimally invasive test, which allows doctors to discover and evaluate a series of information about the characteristics of the tumor and the patient himself through the extraction of a simple blood sample, as well as specific mutations for targeted therapies with clear benefit in the patient's quality of life and survival».
According to André Andraz da Cruz, coordinator of the Oncology Unit of the HPA Health Group, «this technology has evolved and we can now, with the same method and without the need for more invasive procedures, evaluate Circulating Tumor DNA. Among the main benefits, this diagnostic method, carried out in partnership with a North American company, allows the evaluation of molecular residual disease after surgical treatment of cancer, making it possible to customize preventive cancer treatment according to the individual risk of each patient» .
The coordinator also says that, in addition, «it is also possible to monitor the ctDNA during the follow-up of the patient, helping to identify the risk of relapse and thus anticipate and act quickly in the metastatic disease, making it possible to analyze in real time the response to treatment or need for adaptation”.
Comments